

Press Release

Revenue from operations up by 20% & PAT up by 18%

(3rd Quarter FY 2026 Consolidated Results)

Mumbai, 30th January, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 3rd quarter and nine months ended 31st December 2025.

Q3 FY 2026 performance highlights (compared to Q3 FY 2025):

- Revenue from operations at **Rs. 1,375 cr.** against Rs. 1,146 cr.; **up 20%.**
- EBITDA at **Rs. 382 cr.** against Rs. 321 cr.; up 19%; **EBITDA at 28%.**
- Profit after tax at **Rs. 274 cr.** against Rs. 233 cr.; PAT at 20%; **up 18%.**

9M FY 2026 performance highlights (compared to 9M FY 2025):

- Revenue from operations at **Rs. 4,031 cr.** against Rs. 3,478 cr.; **up 16%.**
- EBITDA at **Rs. 1,061 cr.** against Rs. 962 cr.; up 10%; **EBITDA at 26%.**
- The mark-to-market forex loss stood at Rs. 61 cr. Excluding this impact, EBITDA stood at **Rs. 1,123 cr.**, reflecting a 15% growth, with an **EBITDA margin of 28%.**
- Profit after tax at **Rs. 789 cr.** against Rs. 695 cr.; PAT at 20%; **up 14%.**
- ROCE stood at a healthy level of 34% and RONW at 26%.

Segment wise performance:

Markets	Q3		Gwth%	9M		Gwth%
	FY 2025	FY 2026		FY 2025	FY 2026	
Branded Generics						
India	₹ 345	₹ 409	19%	₹ 1,083	₹ 1,250	15%
Asia	₹ 316	₹ 288	-9%	₹ 888	₹ 902	1%
Africa	₹ 173	₹ 230	33%	₹ 617	₹ 679	10%
Sub-Total	₹ 834	₹ 927	11%	₹ 2,588	₹ 2,831	9%
US Generic	₹ 263	₹ 399	52%	₹ 723	₹ 1,052	46%
Africa Institution	₹ 33	₹ 41	22%	₹ 118	₹ 111	-6%
Total	₹ 1,130	₹ 1,367	21%	₹ 3,429	₹ 3,995	16%

As per **IQVIA MAT December 2025**, our India branded generic performance exceeded IPM growth by **28%**. The higher growth came from **Volumes increase**, which exceeded IPM by **47% & New launches**, which exceeded IPM by **59%**.

	Growth %	
Therapy	IPM	Ajanta
Cardiology	13%	5%
Ophthalmology	8%	12%
Dermatology	6%	14%
Pain Management	7%	9%
Overall	9%	11%

ANDA status as at the end of 9M FY 2026 is as below:

Particulars	9M FY 2026
Filed	3
Approval received	2
Launched	3
Total ANDA's commercialized	49
Awaiting approval with US FDA	19
Tentative approval	6

R&D expense:

(Rs. cr.)

Particulars	FY 2025	FY 2026	% to Revenue
Q3	₹ 53	₹ 63	5%
9M	₹ 161	₹ 182	5%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 16:30 hrs. IST (19:00 hrs. SST/HKT, 11:00 hrs. GMT, 06:00 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	January 30, 2026 at 16:30 – 17:30 hrs IST 19:00 – 20:00 hrs SST/HKT 11:00 – 12:00 hrs GMT 06:00 – 07:00 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

For convenience and faster connectivity to the conference, kindly follow the below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the conference Dial-in number you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

Safe Harbour Statement